Ladenburg Thalmann Financial Services
http://www.ladenburg.comLadenburg Thalmann Financial Services, Inc. (AMEX: LTS) provides retail and institutional securities brokerage, investment banking, investment activities, and asset management services as well as equity research. In May of 2008, Ladenburg Thalmann acquired Punk Ziegel & Company to strengthen its trading, research, and investment banking departments. Ladenburg Thalmann is headquartered in Miami, FL.
View Older Stories View More Recent Stories
-
NovaBay Pharma (NBY) Announces Pricing of $3.5 Million Underwritten Public Offering
-
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
-
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
-
Biodexa Pharmaceuticals (BDRX) Prices $5 Million Registered Direct Offering and Concurrent Private Placement
-
Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
-
Trinity Capital Inc. Prices Offering of $100.0 Million of 7.875% Notes due 2029
-
Kingswood U.S. Continues Expansion of Successful In-House Investment Banking Group with Appointment of Tony Tian as Senior Managing Director
-
Osaic Launches Advanced Retirement Income Planning Platform
-
NovaBay Pharma (NBY) Reports Prelim Q2 Revenue of $2.4M
-
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
-
Saratoga Investment Corp. Announces Fiscal First Quarter 2025 Financial Results
-
Ardelyx, Inc (ARDX) PT Lowered to $12.50 at Ladenburg Thalmann
-
Oxford Lane Capital Corp. Prices Public Offering of $100,000,000 8.75% Notes Due 2030
-
Osaic Affiliate Welcomes Engler, Garrow & Roth, Ltd., and Hartmann•Bogan Financial Planning
-
Sonnet BioTherapeutics (SONN) Receives $3.4M From Warrants Exercise
-
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
-
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
-
UroGen Pharma (URGN) Commences Share and Warrant Offering
-
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
-
Ladenburg Thalmann Downgrades Coeptis Therapeutics Holdings, Inc. (COEP) to Neutral
-
UroGen Pharma (URGN) PT Raised to $53.50 at Ladenburg Thalmann
-
Ladenburg Thalmann Starts Red Cat Holdings Inc. (RCAT) at Buy
-
Ladenburg Thalmann Downgrades Entergy Corp (ETR) to Neutral
-
Ladenburg Thalmann Upgrades American Electric Power (AEP) to Neutral
-
Ladenburg Thalmann Upgrades Pinnacle West Capital (PNW) to Buy
-
Calidi Biotherapeutics (CLDI) Exercises $2.1M of Warrants
-
Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
-
Ladenburg Thalmann Reiterates Buy Rating on Palisade Bio Inc. (PALI)
-
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
-
BiomX (PHGE) PT Lowered to $2 at Ladenburg Thalmann
-
NeuroMetrix Reports Q1 2024 Business Highlights
-
Ladenburg Thalmann & Co. Inc. Elevates Executive Leadership with Co-CEO Appointments
-
Capricor Therapeutics (CAPR) PT Raised to $25 at Ladenburg Thalmann
-
Form 13F-NT LADENBURG THALMANN ASSET For: Mar 31
-
SoundHound AI (SOUN) stock jumps on strong subscription demand in Q1
-
Ladenburg Thalmann Downgrades Ready Capital Corp. (RC) to Neutral
-
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
-
Saratoga Investment Corp. Announces Fiscal Year-End and Fourth Quarter 2024 Financial Results
-
Osaic Completes Acquisition of Lincoln Wealth
-
Palisade Bio Inc. (PALI) Announces $4 Million Private Placement of Common Stock, Warrants
-
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
-
TG Therapeutics (TGTX) PT Raised to $40 at Ladenburg Thalmann
-
Ladenburg Thalmann Starts Marker Therapeutics (MRKR) at Buy
-
Alliant Energy (LNT) PT Lowered to $48 at Ladenburg Thalmann
-
Biodexa Pharmaceuticals (BDRX) Enters Exclusive License to eRapa
-
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
-
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
-
Ladenburg Thalmann Starts Spire (SR) at Neutral
-
Gryphon Digital Mining (GRYP) Enters $70M ATM Agreement
-
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering

